High Costs of FDA Approval for Formerly Unapproved Marketed Drugs

JAMA. 2017 Dec 12;318(22):2181-2182. doi: 10.1001/jama.2017.16481.

Authors

Aaron Hakim¹, Ravi Gupta², Joseph S Ross^{3

4}

Affiliations

¹ Yale University School of Medicine, New Haven, Connecticut.
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
⁴ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.

PMID: 29131905
DOI: 10.1001/jama.2017.16481

No abstract available

MeSH terms

Drug Approval*
Drug Costs*
Drug Discovery
Drugs, Generic / economics*
Economic Competition
Government Regulation*
Infusions, Intravenous
Marketing*
Prescription Drugs / economics*
United States
United States Food and Drug Administration*
Vasopressins / administration & dosage
Vasopressins / economics

Substances

Drugs, Generic
Prescription Drugs
Vasopressins